Fluoroplex

Quick links to important sections

Fluoroplex

Method of action: Antitumour, Cytostatic

Treatment option: Keratoses

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluoroplex

Quick Facts

Property Description
Active Ingredient Fluorouracil (5-FU)
Form Topical Solution or Cream
Pharmacological Class Antimetabolite (Antineoplastic Agent)
General Purpose Localized cellular growth control
Origin Synthetic pyrimidine analog

What Type of Medicine is Fluoroplex?

Fluoroplex is a specialized, prescription-only topical pharmaceutical preparation used in dermatological therapy. It is a nucleoside metabolic inhibitor. The drug is typically administered via the topical route onto the skin, formulated as either a solution or a cream. This method of delivery is a key feature of the formulation, allowing it to provide localized chemical therapy, concentrating the therapeutic effect precisely at the area of application. The formulation is recognized for selective action against rapidly proliferating cells.

Composition and Pharmacological Class: What is Fluorouracil?

The active ingredient in Fluoroplex is Fluorouracil (5-FU), which is fundamentally categorized as an antimetabolite. Fluorouracil is a synthetic pyrimidine analog, meaning it is a man-made compound designed to chemically mimic the natural pyrimidine bases required for cellular function. As an antimetabolite, its presence interferes with the essential biochemical pathways necessary for cell division. Fluorouracil is an established anti-cancer agent with a recognized role in global medicine.

General Purpose and Benefit of Topical Antimetabolites

The general purpose of Fluoroplex is to selectively curb the proliferation of atypical or rapidly multiplying cells on the skin surface. This therapeutic utility is driven by its core antimetabolic activity, where it acts to biochemically interrupt the cell’s ability to produce necessary genetic components. By interfering with the rapid cell replication cycle, this agent serves to manage populations of abnormal cells through a highly focused application. This localized action represents its primary advantage over systemic therapies when addressing superficial skin cell abnormalities.

Regulatory References

  1. World Health Organization (WHO)
  2. WHO Essential Medicines

What side effects are possible with Fluoroplex?

Possible side effects and safety information

The safety profile of topical Fluorouracil (the active ingredient in Fluoroplex) is primarily defined by localized dermatological reactions, which are a necessary and anticipated part of the local therapeutic process. These reactions fall under the System-Organ Class of Skin and Subcutaneous Tissue Disorders.


Frequency and Common Reactions

The most frequent adverse events are those occurring at the application site, classified by regulatory authorities as very common or common during the course of treatment. These include:

  • Local pain, burning, and pruritus (itching)
  • Erythema (redness) and inflammation
  • Scaling, crusting, and erosion

Official labeling documents state that the intensity of these local reactions typically increases during the initial weeks of therapy. These effects are generally expected to resolve within one to two months after the treatment has been stopped.


Serious Reactions and Safety Constraints

While systemic absorption is generally low with proper topical use, regulatory documents note the risk of serious systemic toxicity, particularly if excessive amounts are applied over large areas or following accidental ingestion. Rare but severe adverse reactions can involve the Blood and Lymphatic System Disorders (e.g., leukopenia, thrombocytopenia) and Gastrointestinal Disorders.

Crucially, the drug is formally contraindicated in individuals who are or may become pregnant (Pregnancy Category X) due to the documented risk of fetal harm. Safety and effectiveness for the pediatric population have not been established by regulatory authorities. Additionally, individuals with a known Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency are at a significantly increased risk of severe, potentially fatal systemic adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory safety profile for topical fluorouracil (Fluoroplex) distinguishes between local application and severe systemic exposure. Overdosage from routine topical application will ordinarily not cause acute problems; however, the official documentation addresses the critical risk of life-threatening systemic toxicity that can occur from accidental ingestion or significant systemic absorption.


Documented Manifestations and Severe Outcomes

Manifestations of severe systemic toxicity include the onset of severe abdominal pain, bloody diarrhea, vomiting, fever, and chills. These severe signs are associated with potential hematological disorders, such as neutropenia and thrombocytopenia, and inflammation of the gastrointestinal tract.


Mandated Emergency Actions

  • When to seek help: Urgent medical help must be sought immediately if any systemic symptoms (fever, bloody diarrhea, etc.) develop. The medication must be stopped, and a healthcare provider must be contacted immediately to implement symptomatic and supportive care.
  • Accidental Ingestion: For accidental ingestion, official labeling instructs that procedures such as inducing emesis and gastric lavage should be implemented.
  • Population Risk: Patients with a known Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency are identified as being at increased risk for this life-threatening systemic toxicity.

Therapeutic Uses of Fluoroplex

What Fluoroplex Treats: Main Uses and Benefits

Management of Pre-Malignant and Superficial Lesions

Fluoroplex is commonly prescribed for primary dermatologic conditions, including the management of multiple actinic or solar keratoses (precancerous, rough, and scaly skin lesions) and certain cases of superficial basal cell carcinomas when non-surgical methods are applied when appropriate. The application is relevant for easing groups of symptoms, such as roughness, scaling, and crusting, that are associated with these conditions. The therapeutic benefit involves managing conditions presenting with systemic or localized discomfort, which helps manage the potential for the lesions to advance to more invasive forms.


Management of Widespread Sun Damage (Field Therapy)

In clinical settings that involve chronic or fluctuating manifestations of skin damage, particularly across broad areas, Fluoroplex is considered relevant. This is often applied during phases where patients require supportive symptom management for addressing symptom clusters that may become intense or disruptive. By managing both visible spots and unapparent manifestations of sun damage, this broad action contributes to easing the overall symptom load and may help support general well-being across the affected areas.

“...supports the management of wide areas of sun-damaged skin.”


Quick Fact Block

Property Description
Quick Fact: Relief for Roughness, Scaling, and Crusting related to Actinic Keratosis
Therapeutic Context Field-directed treatment of sun-damaged skin
Primary Benefit Provides supportive relief when symptoms interfere with routine activities

Regulatory References

  1. Fluorouracil Cream USP, 5% - DailyMed

Eligibility and Restrictions for Use

The eligibility for using Fluoroplex (Fluorouracil topical) is strictly defined by regulatory bodies and official prescribing information, focusing on patient populations that are permitted, restricted, or explicitly contraindicated from use.


Absolute Contraindications

Fluoroplex must not be used by several specific groups as the use is absolutely forbidden. It is contraindicated for women who are or may become pregnant due to the documented risk of fetal harm. Use is also contraindicated for patients with a known or complete Dihydropyrimidine Dehydrogenase (DPD) deficiency, an enzyme disorder that can cause severe systemic toxicity even with topical application. Furthermore, any individual with a known hypersensitivity or allergy to fluorouracil or any other component in the formulation is strictly prohibited from use.

Age-Group and Conditional Eligibility

The medicine is officially approved for use in adults for its labeled skin conditions. However, the regulatory status of use in younger populations is limited, as the safety and effectiveness in pediatric patients (children) have not been established. For nursing mothers, use is not recommended, and they should not nurse their infants while receiving the drug due to the potential for systemic exposure. Caution is also required when applying the medicine to inflamed or ulcerated skin due to the possibility of increased systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns and restrictions for topical fluorouracil as specified in government regulatory sources.

Pharmacokinetic Interactions and Restrictions

Interaction Type Substance/Class Official Regulatory Statement
Formal Contraindication Antiviral nucleoside drugs (e.g., Brivudine, sorivudine, and analogues) Co-administration is explicitly prohibited.
Mechanism of Risk Dihydropyrimidine Dehydrogenase (DPD) enzyme inhibition These antivirals inhibit the DPD enzyme, which results in a substantial increase in fluorouracil plasma levels and systemic toxicity.
Timing-Separation Rule Brivudine, sorivudine, and analogues A mandatory minimum interval of at least four weeks must elapse between treatment with these drugs and subsequent fluorouracil use.

Other Interaction Cautions

Interaction Type Substance/Class Official Regulatory Statement
Pharmacodynamic Interaction Live, attenuated vaccines Co-administration is generally advised against due to the potential for immunosuppression, which may enhance the risk associated with live vaccines.
Population Constraint DPD enzyme deficiency This deficiency is a formal contraindication for use, as it significantly increases the risk of severe, life-threatening systemic toxicity.

No specific interactions with food, alcohol, or herbal products are formally documented within the core prescribing information by regulators. The interaction profile is critically focused on preventing drug-induced DPD enzyme inhibition and managing the risk associated with congenital DPD deficiency.

Mechanism of Action

Molecular Mechanism of Fluoroplex (Fluorouracil)

Fluoroplex's action is defined by its role as a pyrimidine antimetabolite, which targets the foundational anabolic processes of cell replication. The drug must first be enzymatically activated inside the cell to contribute to a dual-action cytotoxic cascade.


Enzymatic Blockade of Thymidine Synthesis

This mechanism focuses on the antimetabolic action of the drug's active metabolite, FdUMP, which irreversibly inhibits the essential enzyme Thymidylate Synthase ( TS). This blockade halts the de novo production of thymidine, a critical nucleotide, leading to a profound depletion of the DNA building block pool and inducing cell cycle arrest ( S-phase) as a consequence.


Corruption of Genetic Material and Apoptosis Induction

This domain involves the direct structural disruption caused by other active drug metabolites, specifically FUTP and FdUTP. Their fraudulent incorporation into RNA and DNA impairs genetic function and overwhelms the cell’s repair mechanisms. This molecular damage triggers a cytotoxic cascade, characterized by the induction of apoptosis (programmed cell death) in cells exhibiting rapid proliferation.


Mechanistic Selectivity and Constraints

The mechanism is functionally dependent on the high metabolic rate of the cell population, resulting in greater cytotoxicity in actively dividing cells. However, this action is constrained by the balance between activating enzymes and deactivating enzymes like Dihydropyrimidine Dehydrogenase ( DPD), whose high activity can rapidly inactivate the drug and limit the extent of its physiological effect.

Dosage and Administration Information

Official Administration Guidelines

Fluoroplex (topical fluorouracil) is authorized for external use on the skin. Administration is strictly topical, meaning it must not be applied to the eyes, mouth, or other mucosal areas. The medicine is provided in various strengths as a cream or solution, with the 5% concentration being required for the management of Superficial Basal Cell Carcinoma.


The standard regimen for Actinic Keratoses typically involves applying a thin film twice daily, a schedule observed for both the 1% and 5% formulations. For Superficial Basal Cell Carcinoma, the treatment schedule is also twice daily, exclusively using the 5% concentration. Treatment duration is not fixed; application is typically discontinued when the inflammatory reaction progresses to the defined erosion or ulceration endpoint, a process that can take 2 to 6 weeks for Actinic Keratoses and up to 12 weeks for Basal Cell Carcinoma. Complete healing following cessation may require an additional one to two months.


Application involves using fingertips, gloved fingers, or a non-metal applicator, and immediate hand washing is required afterward to contain contact to the treatment area. If a dose is missed, it is generally skipped when it is almost time for the next scheduled dose. Furthermore, the treated area should generally not be covered with an occlusive dressing unless explicitly directed by a healthcare professional. The safety and efficacy of this topical medicine have not been established for use in the pediatric population.

Recent Clinical Evidence

Fluoroplex: Recent Clinical Evidence

Evidence for Use in Actinic Keratosis and Field Damage

The available evidence for topical fluorouracil was studied for multiple actinic keratoses (AKs) and widespread sun-damaged skin (field cancerization). The research base primarily stems from Randomized Controlled Trials (RCTs). These studies were designed to evaluate outcomes related to physical discomfort and the overall number of lesions in the treated area, including comparisons against placebo.

Studies focused on older adults with a high number of sun-damaged lesions. Researchers monitored key outcomes such as lesion clearance measurements and the reduction in lesion counts. Certain large-scale, long-term trials also studies explored whether the application was associated with the subsequent development of new squamous cell carcinoma (SCC). Findings describe patterns observed in the studies where groups using the treatment had measurements related to lesion clearance in the short term. The precise way researchers measured a successful outcome varied across many studies, which means direct comparisons of all trials can be challenging.

Evidence for Use in Superficial Basal Cell Carcinoma

For superficial basal cell carcinoma (sBCC), research was studied for use in specific, non-surgical contexts. The evidence involves clinical trials used for regulatory purposes. The main question that research examined was the Histological Clearance Rate—that is, whether a tissue sample taken after treatment showed the absence of tumor cells. This is a critical factor used in research exploring the outcomes of sBCC treatment.

Studies monitored patients who had sBCC confirmed by biopsy. The studies involved defined application durations, often spanning several weeks. Studies monitored patterns where a notable proportion of patients met the criteria for histological clearance, contributing to the broader evidence landscape. However, research exploring long-term recurrence rates and direct head-to-head comparisons with surgical methods may be limited in number.

Long-Term Research and Durability of Outcomes

Research examined the outcomes during the months and years following the initial treatment phase for actinic keratosis. Long-term studies were conducted to track the recurrence of lesions after the initial clearance measurement. Outcomes measured included the recurrence of lesions and the number of spot treatments needed over periods lasting more than two years.

These trials report how symptoms evolved in the observed populations, and data show patterns related to lesion counts and the use of spot treatments over the observed time intervals. Research provides context but not individual predictions, and the follow-up durations for many of these long-term studies were limited to approximately two to three years. Consequently, data are still emerging, and long-term effects beyond that interval are not fully established.

Areas of Research Uncertainty and Study Gaps

One limitation in the body of research is the heterogeneity of endpoints, meaning researchers in different trials used various metrics to define success, which makes synthesizing all data difficult.

Another key limitation is that comparative evidence is lacking in some areas, particularly concerning direct, long-term comparison against standard surgical excision for sBCC. Furthermore, research focusing on episodes where symptoms become more noticeable over many years provides limited information for long-term outcomes. The evidence quality varies across studies, and findings highlight what is known—and what is still uncertain—about this treatment.

Key Studies & References

  1. Fluorouracil Cream USP, 5% - DailyMed Label

Frequently Asked Questions (FAQ)

Common questions about Fluoroplex (FAQ)

Q: Is Fluoroplex considered a form of chemotherapy?

A: The drug’s mechanism of action is described by regulators as an antineoplastic antimetabolite. This means it works by targeting and interfering with the growth processes of fast-dividing cells. The primary purpose of the topical use is to target the abnormal skin cells in the treatment area.

Q: What kind of skin changes should I expect to see after starting Fluoroplex?

A: According to the official product information, the skin reaction is a necessary part of the treatment process. The skin changes typically observed start with noticeable redness, dryness, and some crusting. The reaction is expected to progress to erosion or ulceration, which is the defined endpoint specified in the official labeling.

Q: Do the side effects of Fluoroplex go away completely after treatment stops?

A: The intense skin reaction that signals the end of the treatment course typically takes time to resolve. Official patient information states that complete healing following the cessation of the medicine may require an additional one to two months. The side effects are expected to subside as the treated area heals fully, which can take several weeks.

Q: Is Fluoroplex known to interact with common vitamins or supplements?

A: Based on the core prescribing information, no specific interactions with food, alcohol, or herbal products are formally documented by regulatory agencies. While vitamins and supplements are not specifically listed, the core patient information does not formally document specific interactions with common items.

Q: Why does Fluoroplex cause redness before the skin starts to heal?

A: The redness and irritation are visible signs that the medicine is working as intended. The drug's mechanism is to interfere with the rapid growth of targeted cells, causing a localized cytotoxic effect (cell death). This action triggers the body's natural inflammatory response in the treatment area, leading to the expected skin changes.

Q: How soon after stopping Fluoroplex can I return to normal skincare?

A: Complete healing following the end of treatment can take one to two months. Official patient information advises that the use of other skin products, including routine moisturizers or cosmetics, should be avoided until the healing process is complete, unless approved by a healthcare provider.

Q: Can Fluoroplex affect the skin on other parts of my body?

A: The product is authorized solely for external, localized use on the skin. While systemic absorption into the body is described as minimal, the medication may still affect surrounding healthy skin if applied beyond the targeted area. Official instructions specify that application should be contained to the treatment site.

Q: Is it normal to feel a burning sensation when applying Fluoroplex?

A: Yes, according to official product information, burning, pain, itching, and general irritation at the application site are listed as common local skin reactions. These sensations are often part of the expected inflammatory process that the medicine induces in the skin.

Q: Will using more Fluoroplex make the condition clear up faster?

A: Official patient instructions advise against altering the prescribed regimen (using more or using it longer). Exceeding the recommended regimen carries the risk of causing unnecessary or increased skin irritation without speeding up the treatment's successful endpoint.

Q: What are the most commonly reported side effects of Fluoroplex?

A: The most commonly reported effects are local skin reactions that occur directly at the application site. These reactions, which are part of the intended mechanism, often include redness, irritation, swelling, dryness, crusting, pain, burning, and itching.

Q: Are there any long-term effects associated with using Fluoroplex?

A: Scarring and changes in skin color have been reported as potential long-term outcomes following the resolution of the inflammatory reaction. However, official information generally lists these as less common occurrences compared to the expected local skin irritation.

Q: Can I use regular moisturizers or cosmetics while I am using Fluoroplex?

A: Official patient information advises against using other skin products, including moisturizers, lotions, or cosmetics, on the treated area. The skin is generally advised to be free of other products during the treatment period unless specific use is approved or instructed by a healthcare provider.

Q: Does sun exposure make the side effects of Fluoroplex worse?

A: Yes, official warnings state that this medication may cause photosensitivity, which is an increased sensitivity to sunlight and ultraviolet light. Patients are advised to take appropriate protective measures during treatment.

Q: What happens if a child accidentally touches skin treated with Fluoroplex?

A: The product should be stored securely away from children, as the safety and effectiveness of this medicine for pediatric patients have not been established. Official warnings state that accidental ingestion or systemic exposure to the drug can potentially lead to severe adverse effects.

Q: Can people with sensitive skin still use Fluoroplex?

A: Official patient information advises against applying the product to skin that is already broken, damaged, or irritated. The labeling advises disclosing any pre-existing skin issues to a healthcare provider before starting treatment.

Q: Is there research evidence supporting the use of Fluoroplex for non-sun-related spots?

A: The safety and effectiveness of this topical medication have been established only for its approved indications: Actinic Keratoses and Superficial Basal Cell Carcinoma. Regulatory documents state that use for other skin conditions has not been established.

Q: Why is Fluoroplex application instructions so precise?

A: The precise application instructions are designed to manage the risk of increased systemic absorption. Applying the medication to open cuts, broken skin, or ulcerated areas can increase the amount of drug that enters the bloodstream, potentially leading to adverse effects outside of the treatment area.

Q: Does the color or consistency of Fluoroplex change over time in the tube?

A: Official regulatory guidance focuses on providing specific storage conditions, such as temperature limits, and stability timelines after the product is opened. While these instructions help ensure the medication remains effective, they do not generally detail whether any specific changes in the product's color or consistency are expected over time.

Q: Can Fluoroplex be used by older adults with multiple health issues?

A: Based on reported clinical experience, official information has not identified differences in safety or effectiveness when comparing elderly patients to younger patients. However, the presence of DPD enzyme deficiency or other contraindications remains a factor that requires evaluation regardless of age.

Q: What should I do if I accidentally apply Fluoroplex to an area that is cut or irritated?

A: Official product information advises against applying this medicine to broken, cut, or damaged skin. Applying it to irritated areas may increase the amount of drug absorbed into the body, raising the potential for systemic adverse effects.

Q: Is Fluoroplex known to cause sensitivity to light?

A: Yes, according to official warnings, the use of this medicine may cause photosensitivity, which is a severe increase in skin sensitivity to sunlight and other sources of ultraviolet light. Patients are advised to take appropriate protective measures during treatment.

Q: How does the official research categorize the safety of Fluoroplex during pregnancy?

A: Regulatory information states that the drug can cause fetal harm and is categorized as Pregnancy Category D. Due to the mechanism of action and findings from animal studies, use of this medication is generally contraindicated during pregnancy.

Q: Does Fluoroplex have any effect on blood test results?

A: Topical application is generally associated with minimal systemic absorption into the bloodstream. However, certain reported systemic adverse effects, such as unusual bleeding or bruising, are symptoms that may warrant monitoring via blood tests.

Q: Is there a generic version of Fluoroplex available?

A: Fluoroplex contains the active ingredient fluorouracil. The active ingredient is also available in other topical fluorouracil products, which include generic creams and solutions.

Q: What are the published success rates for Fluoroplex in treating its main condition?

A: Clinical data published in official regulatory documents include efficacy results for the approved conditions. For the treatment of Superficial Basal Cell Carcinoma, clinical studies have reported a success rate of approximately 93% based on the treatment of 113 lesions.

Q: Does the regulatory body classify Fluoroplex as a high-risk medication?

A: Regulatory documents include multiple warnings and contraindications that highlight the potential for serious adverse reactions. Use is strictly prohibited for patients with DPD enzyme deficiency and during pregnancy due to the potential for severe harm.

Q: What is the experience of people using Fluoroplex on their hands or arms?

A: Official prescribing documents note that the length of treatment can vary based on the location of the affected area. Specifically, lesions located on the hands and forearms tend to respond more slowly to treatment compared to those located on the face or trunk.

Q: Are there any documented cases of overdose with topical use of Fluoroplex?

A: Official patient warnings caution that using more than the prescribed amount of cream or using it too often may lead to increased absorption into the bloodstream. This increased systemic absorption can potentially result in adverse effects that involve the digestive system, such as stomach pain and bloody diarrhea.

Q: What does the term 'lesion' mean in the context of Fluoroplex treatment?

A: In the context of the official product documentation, the term 'lesion' refers to the abnormal or diseased areas of skin that the medicine is approved to treat. These include the Actinic Keratoses and Superficial Basal Cell Carcinomas specified in the indications for use.

Q: What is the distinction between Fluoroplex and Efudex?

A: Fluoroplex and Efudex are two different brand names for topical products that contain the same active medicinal ingredient: fluorouracil. They are both used to treat the same approved skin conditions.

Q: Can Fluoroplex be used to treat viral warts?

A: Safety and effectiveness of this topical medication have not been established for treating skin conditions other than its approved indications. These indications are limited to Actinic Keratoses and Superficial Basal Cell Carcinomas.

Q: What data exists on the safety of Fluoroplex during breastfeeding?

A: Official information states that it is not known whether this drug passes into human milk. Due to the potential for serious adverse reactions in an infant, the labeling indicates that a decision should be made to either discontinue nursing or discontinue use of the drug.

Q: Does the treatment cause scarring in most cases?

A: Scarring is not typically listed as a common or expected outcome of the treatment. While scarring has been reported as a potential side effect, it is generally listed in official documentation as a less common or rare occurrence compared to the expected local skin irritation and subsequent healing.

How should Fluoroplex be stored and disposed of?

How to Store and Dispose of Fluoroplex

Official Storage Requirements

Fluoroplex (fluorouracil) cream must be stored at Controlled Room Temperature, typically between 15 C to 30 C (59 F to 86 F). It is essential to keep the medication in its original container, tightly closed, and protect it from freezing and excessive heat or moisture. For safety, the product must be stored out of the sight and reach of children and pets.

Stability and Disposal

Some formulations may have a limited in-use shelf life (e.g., 90 days) after the original tube is opened. Dispose of unused or expired cream according to local regulations, often via an official medicine take-back program. Do not flush this medication down the toilet or dispose of it in household trash unless instructed by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoroplex found in:

A-Z Index: